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Supporting Information
Poly(ethylene glycol) (mPEG 5k -NH 2 ) was purchased from Biochempeg (USA). 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid N-succinimidyl ester (RAFT-NHS), 2-bromoisobutyryl bromide, 2-(diisopropylamino)ethyl methacrylate (DPA), 2,2'-Dipyridyl (bpy), 2-hydroxyethyl methacrylate (HEMA), oxalyl chloride, bromotrimethylsilane, 2,2 -azobis(2-methylpropionitrile) (AIBN), 2 ,7 -dichlorofluorescin diacetate (DCFH-DA), methylene blue (MB) and methyl thiazolyl tetrazolium (MTT) were obtained from SigmaAldrich. Dimethyl(2-hydroxyethyl) phosphonate was purchased from TCI. (S)-(+)-Camptothecin (CPT) was purchased from Chem-Impex (USA). -Lapachone (La) was purchased from ApexBio (USA). The iron oxide nanoparticles (IONPs) and upconversion nanoparticles (UCNPs) were prepared according previous reports.
[ 1] Synthesis of CPTMA monomer CPTMA was synthesized according previous report (Scheme S1). [2] Briefly, HEMA (40 mmol) was dissloved in anhydrous dichloromethane (30 mL). Then oxalyl chloride (60 mmol) in anhydrous dichloromethane (50 mL) was dropwise added into the HEMA solution at 0 °C.
After 1 h of reaction, the excess oxalyl chloride and solvent were removed under reduced pressure to afford a colorless oil. Subsequently, CPT (5.75 mmol) and triethylamine (9.1 mmol) in anhydrous dichloromethane (50 mL) was added into the prepared colorless oil 2 solution (9.1 mmol). After 1 h of reaction, the mixture was filtered and the solvent was evaporated under reduced pressure. Then the concentrated mixture was allowed to afford chromatographic separation (silica gel, dichloromethane/ethyl acetate (2:1, v/v)) to yield CPTMA prodrug monomer as a pale yellow solid.
Synthesis of PEG-PCPT
PEG-PCPT (Scheme S2)
The mixture was precipitated into an excess of ethyl acetate to generate PEG-PCPT. DMBiBEP and BiBEP were synthesized according previous report (Scheme S4). [3] In brief, dimethyl(2-hydroxyethyl) phosphonate (10 g), triethylamine (10.3 mL) were dissloved in dichloromethane (120 mL). Then 2-bromoisobutyryl bromide (8.9 mL) was slowly added to the mixture at 0 °C. The reaction was held at room temperature for 12 h. The mixture was washed with saturated brine (2 × 150 mL) and water (1 × 100 mL). The organic layer was 3 separated and dried over anhydrous MgSO 4 . The DMBiBEP was obtained after filtration and evaporation of the solvent.
Synthesis of PEG-PDPA
PEG
To synthesize BiBEP, DMBiBEP (0.5 g) was dissloved in dichloromethane (5 mL).
Bromotrimethylsilane (1.3 mL) was added in a dropwise manner, and the mixture was stirred at room temperature for 12 h. After evaporation of the solvent, methanol (5 mL) was added and the mixture was stirred at room temperature for another 12 h. The solvent was evaporated and the BiBEP was obtained after washing with ether.
Synthesis of phosphonated poly DPA (P-PDPA)
P-PDPA was synthesized by atom transfer radical polymerization (ATRP) (Scheme S5).
°C
The mixture was precipitated into methanol/water to generate P-PDPA.
Preparation of PDPA-IONPs and PDPA-UCNPs
The PDPA-IONPs were prepared as follows: (50 mg) was dissolved in THF (5 mL) and then added into IONPs THF (5 mL, 1mg mL -1 ). The above mixture was heated to 50 °C 
Characterizations
The morphology of the HRNMs was observed by Tecnai TF30 transmission electron microscope (TEM) (FEI, Hillsboro, OR). The effective particle diameters and zeta potential of the samples were determined by a SZ-100 nano particle analyzer (HORIBA Scientific, USA)
at room temperature. UV-vis-NIR absorption spectra were measured by Genesys 10S UV-Vis spectrophotometer (Thermo Scientific, Waltham, MA).
In vitro drug release
The in vitro drug release behaviors of the samples were evaluated by a dialysis method. The samples were dispered in 2 mL of media and added to dialysis bags (MWCO: 1000 Da) and placed in 20 mL of environmental media. At appropriate time points, 2 mL of the medium was taken out and replaced with the same amount of fresh medium. The amounts of the released La and CPT were measured by HPLC. The amount of the released Fe was measured by inductively coupled plasma mass spectrometry (ICP-MS).
In vitro cell experiments
The in vitro cell cytotoxicity, ROS generation study and antitumor activity study were assessed on A549 cell line, which was purchased from American type culture collection (ATCC).
To assess the cell cytotoxicity of DIONPs and DUCNPs, A549 cells were seeded into 96-well plates at a density of 3000 cells per well and incubated at 37 °C in 100 L of DMEM with 10% FBS under a 5% CO 2 atmosphere for 24 h. Then the samples were added to each well and the cells were incubated at 37 °C for an additional 48 h. After the incubation, the relative cell viabilities were measured by the MTT assay. 
In vivo PET imaging
NOTA-PDPA was synthesized for 64 Cu labeling. The NOTA-PDPA was encapsulated into
LaCIONPs during preparation and then labeled with 64 Cu, obtaining 64 Cu-LaCIONPs. Then the sample solution (100 L, 140 Ci) was intravenously injected into A549 tumor-bearing
mice. An Inveon small-animal PET scanner (Siemens, Erlangen, Germany) was used for the scanning at indicated time points after injection. At 48 h post-injection, the mice were sacrificed and the major organs were collected and assayed for radioactivity using a gamma counter. The percent of injected dose/gram of tissue (%ID/g) was then calculated.
In vivo therapy
A549 tumor-bearing mice were randomly divided into 6 groups (n = 5): control group, free CPT group, LaDUCNPs group, LaDIONPs group, LaCUCNPs group and LaCIONPs group. 
